

Figure 1: X-Ray Powder Diffraction (XRPD) pattern of Type β polymorph of 5-(2-(6-(2,2-Difluoro-2-phenylethoxy)hexylamino)-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one heminapadisylate.




Figure 2: DSC pattern of Type β polymorph of 5-(2-(6-(2,2-Difluoro-2-phenylethoxy)hexylamino)-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one heminapadisylate of the invention.




Figure 3: TGA pattern of Type β polymorph of 5-(2-(6-(2,2-Difluoro-2-phenylethoxy)hexylamino)-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one heminapadisylate of the invention.




Figure 4: FT-IR pattern of Type β polymorph of 5-(2-(6-(2,2-Difluoro-2-phenylethoxy)hexylamino)-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one heminapadisylate of the invention.




Figure 5: X-Ray Powder Diffraction (XRPD) pattern of Hydrate polymorph of 5-(2-(6-(2,2-Difluoro-2-phenylethoxy)hexylamino)-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one heminapadisylate, hemihydrate of the invention.




Figure 6: DSC pattern of Hydrate polymorph of 5-(2-(6-(2,2-Difluoro-2-phenylethoxy)hexylamino)-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one heminapadisylate, hemihydrate of the invention.




Figure 7: TGA pattern of Hydrate polymorph of 5-(2-(6-(2,2-Difluoro-2-phenylethoxy)hexylamino)-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one heminapadisylate, hemihydrate of the invention.




Figure 8: FT-IR pattern of Hydrate polymorph of 5-(2-(6-(2,2-Difluoro-2-phenylethoxy)hexylamino)-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one heminapadisylate, hemihydrate of the invention.




Figure 9: X-Ray Powder Diffraction (XRPD) pattern of samples of the alpha, beta and Hydrate polymorphs of 5-(2-(6-(2,2-Difluoro-2-phenylethoxy)hexylamino)-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one heminapadisylate.

